REACH Trial Shows 51% Malaria Drop With Maximum-Tolerated Hydroxyurea in African Sickle Cell Children

The multicenter REACH study enrolled children in Angola, DRC, Kenya and Uganda between 2014 and 2016. Participants started fixed-dose hydroxyurea for six months then escalated to maximum tolerated dose; infections were captured retrospectively via clinical records. Incidence of both malarial and non-malarial infections fell with rising doses, contradicting earlier theoretical concern that neutropenia would increase infection risk in low-resource settings.

Prior REACH reports had already documented reduced vaso-occlusive events and transfusions; this infection analysis extends those findings across more than ten years. The absence of increased malaria or bacterial disease, even at peak dosing, removes a major barrier cited by clinicians in sub-Saharan Africa where 80% of global sickle-cell births occur.

Policy impact is immediate: ministries can now justify broader hydroxyurea access without requiring intensive infection surveillance. Remaining gaps include long-term malignancy surveillance and cost-effectiveness data at scale. Next studies must test implementation models that integrate hydroxyurea into routine primary-care pathways rather than specialist clinics.

Evidence quality is high for an open-label multicenter trial but limited by retrospective infection ascertainment and lack of placebo control; a cluster-randomized rollout with active surveillance would strengthen causal claims.